

Comprehensive Cancer Center Erlangen-EMN

Director

Prof. Dr. med. Matthias W. Beckmann

Address

CCC Erlangen-EMN Office
Östliche Stadtmauerstraße 30
91054 Erlangen
Phone: +49 9131 8547029
Fax: +49 9131 8536393
ccc-direktion@uk-erlangen.de
www.ccc.uk-erlangen.de
Hotline: 0800 8510085

Aims and structure

The Comprehensive Cancer Center Erlangen – European Metropolitan Region of Nuremberg (CCC ER-EMN) is an interdisciplinary center of excellence established to coordinate medical care, research, and teaching. For patients, relatives, physicians, and scientific researchers, the CCC ER-EMN is the central contact for all questions connected to cancer diseases.

The center organizes further education and training courses on topics in oncology and coordinates research projects. In addition, it runs a free tumor consultancy service for patients and their relatives.

CCC ER-EMN was founded in December 2007 as the Erlangen University Cancer Center by members of staff at the UK Erlangen and the Faculty of Medicine. Cooperation agreements with Bamberg hospital (Sozialstiftung Bamberg), Bayreuth hospital (Klinikum Bayreuth GmbH) and Amberg hospital (Klinikum St. Marien Amberg) were established. All four sites have oncological centers certified in accordance with the German Cancer Society criteria.

Under the aegis of CCC ER-EMN, there is a total of 22 certified organ cancer centers, 13 focal points, and 26 interdisciplinary tumor conferences that are responsible for optimized patient care and multidisciplinary development of clinical pathways according to the most up-to-date standards.

Interdisciplinary treatment based on a personalized plan

At the CCC ER-EMN institutions, all types of cancer are diagnosed and treated as gently and effectively as possible using the most advanced modern technologies. Specially trained nurses and psychologists are there to assist patients during the treatment phase. Due to the high level of research activity at the CCC ER-EMN, patients have access to innovative therapeutic

approaches. All treatment decisions are taken jointly by the experts in each specialty, at meetings known as “tumor conferences”.

Patients suspected to have a complex oncological syndrome or with advanced/metastatic solid cancers are presented in the cross-regional molecular tumor board and can be tested with a comprehensive cancer-/genpanel. The results improve clinical decision making of innovative therapies.

The information brochure „Side by Side“ of the CCC Erlangen-EMN offers relevant information on diagnosis, therapy, and other cancer related topics.


Aims of CCC ER-EMN

- Interdisciplinary and inter-organizational optimization of care for oncology patients
- Interdisciplinary and inter-organizational support for cancer research at the level of clinical research, epidemiological research, translational research, and basic research
- Support for regional collaboration in the field of tumor diagnosis, treatment, and follow-up care together with other hospitals, particularly university teaching hospitals, specialist oncology practices, specialist physicians and family doctors, hospices, and rehabilitation facilities
- Support for interdisciplinary and inter-organizational teaching in oncology
- Recruitment of highly talented junior staff for clinical care and research

Research

If possible, patients are treated in the framework of clinical studies. This means that they directly benefit from clinical progress and can be treated in accordance with the highest safety standards in the context of clinical trials. Links with the Center for Clinical Studies (CCS; compare own report) and with the study coordination offices at the cooperating hospitals are available for this purpose.

Patient care and clinical research at UK Erlangen are supported by a structured IT approach. This consists mainly of the electronic patient file system Soarian™ and the data warehouse tool Cognos™. Supplementary to these IT systems, there are commercial IT solutions for cancer registry, trial management, and biobanking. Physicians and patients can soon search the CCC-website to get information about ongoing clinical trials. Clinical trials are important for innovation and the treatment of cancer patients. Clinical trials of all phases are conducted at the CCC Erlangen-EMN.



Graphic: CCC/nandodesign.de

Data for cancer patients at CCC ER-EMN are documented in three clinical cancer registries. This enables scientists in the field of cancer research to analyze disease courses and investigate and develop improved treatments. Research on biomaterials forms the basis for new discoveries. For this purpose, a biomaterials bank has been set up for tumor tissue, tissue from healthy controls, and also body fluids (e.g. pleural effusions, urine, etc.) as well as DNA from tumor patients and control individuals. These biomaterials are used with the consent of the patients involved and enable the development of investigational methods at the highest scientific standards to pursue major research goals speeding up medical progress with new discoveries and the development of new forms of treatment. The core units “tissue based automated RNA and DNA diagnostics” and “cell line construction” have been set up at the CCC ER-EMN.

Teaching

The center offers physicians, private medical practices, and hospitals the opportunity to receive further training in the various fields involved in oncology and to consult with experts in difficult treatment cases. In addition, CCC ER-EMN provides a series of lectures for physicians and scientists in the field of cancer research.

CCC Comprehensive
Cancer
Center

Erlangen-EMN
Europäische Metropolregion Nürnberg